Smoke-Free Living Study
Condition: Additional, Effective Methods to Stop Smoking
Study type: Interventional
Phase: Phase 1

Summary: 
      The goal of this study is to provide you with an effective treatment for reducing the
      physical and emotional stress that can occur during the early phase of being without
      cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will
      receive counseling and a supply of Champix, a medication to help suppress the symptoms of
      nicotine withdrawal.

      Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking
      cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant
      increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of
      varenicline (Champix) and IVR treatment.
    

Detailed description: 
      The automated IVR uses algorithms and sophisticated speech recognition (computerized) to
      engage smokers on the telephone; gather information, provide reinforcing messages and triage
      them to a study nurse for call-back within 2 working days if either the smoker or nurse
      identify help is required. The technology recognizes the smoker's verbal responses, documents
      them and thereby assists in guiding further follow-up. IVR is a low-cost, high-yield way of
      contacting smokers when they would not ordinarily be contacted.

      When prospective subjects call to register, a voice message will ask them to leave their
      name, telephone number, and register their choice of session date they would like to attend
      (the telephone message will list the 3 choices of session dates - as outlined on the poster).

      Each session is a combined Information, Screening, and Recruitment session, which will be
      held once a week at St. Paul's Hospital (for a period of 3 weeks). The sessions will begin
      with a presentation by the participating physician, and will be group-based. The sessions
      will include information about smoking, smoking cessation, varenicline (Champix), eligibility
      for the study, and the relevance of the questionnaire about demographics, motivation, stress,
      and smoking, and the consent form (see questionnaire attachment). (The consent forms will be
      distributed to the group so they may view them while their relevance is discussed). Potential
      subjects will be given an information package including the Canadian Cancer Society booklets
      "For Smokers Who Don't Want to Quit" and "For Smokers Who Want To Quit" (see booklet
      attachments in 9.8).

      Potential subjects will then be asked to read the consent form. If they think they meet the
      inclusion and exclusion criteria and are interested in proceeding they will meet with the
      physician in private (in a conference room across the hall) after the session. The physician
      will determine their eligibility (as per inclusion and exclusion criteria). A Healthy Heart
      volunteer will then witness their signing of the consent form. They will be asked to sign a
      second consent form that will be marked "copy" and given to them.

      There is no time limit to sign the consent form. If potential subjects would like to make an
      appointment with the study nurse to come in to sign the consent at a future date, they may do
      so. In this situation, the following study procedures would be completed at this later date.

      Study Procedures If subjects meet the inclusion and exclusion criteria and agree to
      participate in the study, they will be asked to complete the questionnaire (20 minutes): the
      Stage of Change algorithm will determine stage or readiness for change, pros' and con's of
      change will be assessed using the Decisional Balance Scale, smoking self-efficiency will be
      measured using the Self-Efficacy and Temptation Scale, and psychological distress will be
      measured using the Stop-D Scale (see questionnaire attachment in 9.1). The answers to the
      questionnaire provide information about the phenotype - who responds to varenicline (Champix)
      and IVR treatment and who does not.

      Subjects' weight and waist circumference will be measured and recorded. They will choose a
      target quit date at this time. It will be between 8 and 14 days after starting varenicline
      (Champix). Subjects will give their quit date, preferred calling time, and telephone number
      for the IVR technology (see vital signs and IVR attachment in 9.1).

      Subjects will then receive a 12-week supply of varenicline (Champix). The study nurse will
      hand it to them. They will be instructed to take 0.5 mg on days 1-3, 0.5 mg twice a day (once
      in the morning and once in the evening, at about the same time each day) on days 4-7, and 1
      mg twice a day until the end of their supply (the end of week 12).

      They will also be given a 12-month diary calendar and asked to record the number of
      cigarettes smoked on the corresponding dates (see diary attachment in 9.1). They will be
      asked to bring this diary calendar in to the final visit at week 52.

      The Integrated Voice Response (IVR) will make a call on the quit date, day 3, 8, and 11, and
      then every 2 weeks. The IVR is a sophisticated, computerized, voice response technology that
      tracks subjects' progress using a detailed series of questions.

      If any response suggests the subject is having trouble remaining smoke-free or if they have
      started smoking again, a study nurse will call to help get the subject back on track and not
      smoking. This smoking cessation counseling will include assessment of whether the subject is
      taking varenicline (Champix) in the prescribed dosage, whether they are experiencing any
      adverse effects, the number of cigarettes and time of day they are smoking, triggers for
      smoking, and assistance to develop coping mechanisms to reduce these triggers. If the subject
      is not experiencing any adverse effects they will be advised to continue taking varenicline
      (Champix). If they are still smoking, they will be advised to try not to increase the number
      of cigarettes smoked per day.

      After the 12th week of treatment, all subjects who have quit smoking will come in for a brief
      (15 minutes) appointment. An exhaled carbon monoxide level will be measured and recorded by
      the study nurse to assess smoking status. Lung / breath carbon monoxide measurements (CO)
      will be made using a Roxon Micro Smokerlyzer; CO should be 0 - 10 ppm. in a non-smoker.

      Subjects who have quit smoking (usually about 44% of those who receive Champix and 15% of
      those who receive IVR) will be equally randomized into 2 groups matched by level of
      motivation (a score of 7 or higher - question #30, pg. 5 of questionnaire) and level of
      addiction (a score of 7 or higher - question #17 - #24, pg. 3 - 4 of questionnaire).
      Randomization will be done by manual calculation of these two scores.

      The intervention group will continue to receive IVR support every 2 weeks for 9 months (weeks
      13 - 52) and the control group will no longer receive IVR support.

      Subjects who are still smoking, identified by the IVR system, and not eligible for
      randomization, do not need to attend the visit after week 12. They will continue in the study
      and return for the final visit at week 52 with their diary.

      At week 52, all subjects will come in for a final appointment (approximately 35 minutes) and
      complete the same questionnaire administered at the initial baseline visit. Subjects will be
      asked to bring their diary. Weight and waist circumference will be measured and recorded by
      the study nurse. For those Subjects who have stopped smoking, a final exhaled carbon monoxide
      level will be measured and recorded by the study nurse to assess smoking status.

      There will be a total of 3 clinical visits for participants (initial baseline visit, 12 week
      visit, and 52 week visit) who have stopped smoking by week 12. There will be a total of 2
      clinical visits for those who have not stopped smoking by week 12 (initial baseline visit and
      52 week visit). There will be approximately 27 telephone contacts for the intervention group
      and 9 telephone contacts for the control group. Each telephone call is approximately 3 - 5
      minutes.

      The intervention group (extended IVR) will be asked to dedicate 7 hours and the control group
      (not receiving extended IVR) will be asked to dedicate 3 hours to the study.

      Subjects will be reimbursed $10.00 for parking expenses at the final visit, week 52. Other
      expenses such as time away from work, etc. will not be reimbursed.
    

Intervention name(s): Extended IVR (integrated voice response technology); Varenicline (Champix); IVR treatment
Intervention type(s): Behavioral; Drug; Behavioral
Intervention description(s): See detailed description; See detailed description; See detailed description
Intervention MeSH terms: Varenicline
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: smoking; Champix; Integrated Voice Response technology